



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAME OF INVENTOR	ATTORNEY DOCKET NO.	CONTINUATION NO.
09/654,328	09/01/2000	Michael B. Brenner	H08017187(ERP MAT)	5703

7590

01/14/2003

Elizabeth R Plumer
Wolf Greenfield & Sacks P C
600 Atlantic Avenue
Boston, MA 02210

EXAMINER

HADDAD, MAHER M

ART UNIT

PAPER NUMBER

3644

DATE MAILED: 01/14/2003

14

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	09/654,328	BRENNER ET AL.	
	Examiner	Art Unit	
	Maier M. Haddad	1644	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 04 November 2002.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1, 3, 5, 6, 16, 44, 45 and 50-56 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, 3, 5, 6, 16, 44, 45, and 50-56 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
 If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) ☐ All b) ☐ Some c) ☐ None of:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
 * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
 a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) Paper No(s). _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: |

RESPONSE TO APPLICANT'S AMENDMENT

1. Applicant's amendment, filed 11/04/02 (Paper No. 11), is acknowledged.

Claims 1, 3, 5, 6, 16, 44, 45, and 50-56 are pending and under consideration in the instant application.

2. The following new ground of rejection is necessitated by the amendment filed on 11/04/02, paper No. 12.

3. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 1, 3, 5, 6, 16 and 44-45 and 50-56 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a method for treating a subject having a an inflammatory joint disorder comprising administering locally to a synovium of the subject an anti cadherin-11 antibody provided applicant provides support as how to extrapolate data obtained from *in vitro* assay to the development of effective *in vivo* human therapeutic methods as presented in the previous Office Action. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or the invention commensurate in scope with these claims essentially for the same reasons set forth in the previous Office Action, paper No. 10, mailed 4/26/02.

Applicants' arguments, filed 11-04-02, Paper No. 11 have been fully considered but not persuasive.

Applicant argues in conjunction with references and examples that *in vivo* data is not required for enablement for *in vivo* methods. Applicant argues that (1) the art is familiar with treatment of inflammatory joint disorders and antibody therapies. (2) the issue of correlation between the *in vitro* results and *in vivo* methods centers on whether the examples can be considered working examples and the absence of a working example is not sufficient to render an invention non-enabled if all other factors point toward enablement. (3) whether the *in vitro* data presented correlates with the claimed methods is dependent on the state of the prior art. (4) Applicants submitted experimental evidence to demonstrate the enabling nature of the specification as filed, wherein cadherin-11-Fc fusion protein parenterally administered to mice having serum-induced arthritis caused reduction in clinical symptoms

Art Unit: 1644

of inflammatory arthritis including reduced ankle thickness, delay in arthritis onset, and decreased maximal arthritic index.

As noted previously in paper No. 10, the exemplification in the specification is drawn to the blocking of cadherin-11 from human type B synoviocytes using *in vitro* adhesion assays. While such *in vitro* assay may provide an indication that particular compounds/compositions are appropriate to target for *further experimental consideration*. Applicant's disclosure does not appear to have provided the skilled artisan with sufficient guidance and support as how to extrapolate data obtained from *in vitro* assay to the development of effective *in vivo* human therapeutic methods, commensurate in scope with the claimed invention.

Examiner notes that the post-dated data presented dealt with an active immunization with the cadherin-11-Fc fusion protein versus the instant claimed passive immunotherapy with antibodies to cadherin-11. Examiner agrees with applicant's assertion that the art is familiar with treatment of inflammatory joint disorders and antibody therapies, however, *in vivo* efficacy of an immunosuppressive compound tested solely in vitro unpredictable. Kahan states that "no in vitro immune assay predicts or correlates with in vivo immunosuppressive efficacy; hence, there is no surrogate immune parameter as a basis of immunosuppressive efficacy and/or for dose extrapolation from in vitro systems to in vivo conditions" (Curr. Opin. Immuno. 4:553:560, 1992; see entire document, particularly page 558, column 2).

In view of the absence of a specific and detailed description in Applicant's specification of how to effectively use the methods as claimed, and absence of working examples providing evidence which is reasonably predictive that the claimed methods are effective for *in vivo* use, and the lack of predictability in the art at the time the invention was made, an undue amount of experimentation would be required to practice the claimed methods with a reasonable expectation of success

5. No claim allowed

6. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Art Unit: 1644

7. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maher Haddad, whose telephone number is (703) 306-3472. The examiner can normally be reached Monday to Friday from 8:00 to 4:30. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached at (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.

Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The CM1 Fax Center telephone number is (703) 305-3014.

Maher Haddad, Ph.D.
Patent Examiner
Technology Center 1600
January 13, 2003


CHRISTINA CHAN
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600